Increasing expression of substance P and calcitonin gene-related peptide in synovial tissue and fluid contribute to the progress of arthritis in developmental dysplasia of the hip

What Was Tested

The paper reports a study of CGRP (Calcitonin Gene-Related Peptide) and Substance P, published as an observational study.

Developmental dysplasia of the hip (DDH) is a common musculoskeletal disorder that has pain and loss of joint function as major pathological features.

In the present study, the researchers explored the mechanisms of possible involvement and regulation of substance P (SP) and calcitonin gene-related peptide (CGRP) in the pathological and inflammatory processes of arthritis in DDH.

Who Took Part

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

Blood, synovial tissue and fluid samples were collected from patients diagnosed with different severities of DDH and from patients with femoral neck fracture.

The proinflammatory effects of SP and CGRP on synoviocytes obtained from patients with moderate DDH were investigated in vitro by real-time PCR and ELISA.

How the Study Was Run

Levels of SP, CGRP and inflammatory cytokines in synovium and synovial fluid (SF) in the different groups were evaluated by immunohistochemistry, real-time PCR and enzyme-linked immunosorbent assay (ELISA).

Correlations between neuropeptides and inflammatory cytokines in SF were evaluated by partial correlation analysis.

The mechanisms of those effects were evaluated by Western blot analysis and nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) DNA binding assay.

What Was Measured

The subject headings attached to it are Arthritis, Calcitonin Gene-Related Peptide, Disease Progression, Gene Expression Regulation, Hip Dislocation, Congenital, Substance P and Synovial Fluid.

What This Means in Plain Language

This is an observational study of CGRP (Calcitonin Gene-Related Peptide) and Substance P.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Arthritis research & therapy), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page and the Substance P compound page, all human trials.